Skip to main content
. Author manuscript; available in PMC: 2012 Feb 4.
Published in final edited form as: Nat Med. 2011 Jun 26;17(7):875–882. doi: 10.1038/nm.2377

Figure 5.

Figure 5

Cdk1 inhibition sensitizes cancer cells to PARP inhibition in vivo. (a) Growth of NCI-H1299-cdk1 xenografts in mice administered regular or doxycycline-containing diets, treated with vehicle or AG014699 over days 1–23. Mean relative tumor volume (RTV) (n=6), is expressed compared to tumor volumes on day 1. (b) RTV for individual mice treated in (a) at day 13. (c) Cdk1, cdk2, γ-H2AX and tubulin protein expression from representative tumors in mice sacrificed on day 23 measured by western blot. (d) Growth of NCI-H1299 xenografts over 19 days in mice receiving the indicated treatments. V, vehicle. Tumor size is presented as the mean tumor volume (n = 6) relative to day 1. (e) RTV for individual mice treated in (d) at day 13. (f) Change in weight of individual mice treated as in (d) at day 18. (g) Immunohistochemical analysis for BRCA1 [pS1189], total BRCA1 and γ-H2AX focus formation, and Aurora B and TUNEL staining in NCI-H1299 xenografts harvested from mice treated for 5 continuous days with the indicated treatments. (Left) Representative sections, stained as indicated. (Right) mean ± SE foci- or staining-positive cells. *’s indicate statistically significant P values. Scale bars, 10 µM.